Platinum based chemoradiotherapy is the standard of care for inoperable non-small cell lung cancer (NSCLC). With evidence that NSCLC can have a dose dependent response with stereotactic ablative radiotherapy (SABR), we hypothesize that a SABR boost on residual tumor treated with chemoradiotherapy could increase treatment efficacy. The purpose of this study was to determine feasibility of such an approach.
from Imaging via alkiviadis.1961 on Inoreader https://ift.tt/2Exm3Xj
Δευτέρα 9 Απριλίου 2018
Stereotactic ablative radiotherapy after concomitant chemoradiotherapy in non-small cell lung cancer: A TITE-CRM phase 1 trial
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
As demonstrated by the market reactions to downgrades of various sovereign credit ratings in 2011, the credit rating agencies occupy an impo...
-
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2iI98XR via IFTTT
-
Abstract Despite the recent promising results of clinical trials using human pluripotent stem cell (hPSC)-based cell therapies for age-rel...
-
Spindle cell/pleomorphic lipoma is an uncommonly encountered benign neoplasm that is usually found in the subcutaneous tissues. Rare cases r...
-
Lichtenstein intervention is currently the classic model of the regulated treatment of inguinal hernias by direct local approach. This “tens...
-
Abstract Deducing the scapular positions of extinct tetrapod skeletons remains difficult, because the scapulae and rib cage are connected ...
-
Abstract Introduction Radiotherapy is essential for achieving and maintaining local control in head and neck rhabdomyosarcoma (HNRMS) pa...
-
Background Understanding the cultural characteristics of healthcare organisations is widely recognised to be an important component of patie...
-
Facial asymmetry in a crying newborn can be due to a variety of different causes. Neonatal asymmetric crying facies (NACF) is a specific phe...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου